Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1300 participants.
Also called NCT07866066
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,300 participants
- Sponsor
- Registry
-
NCT07866066 -
2025-523772-22-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT07866066. Randomized; no masking; primary purpose treatment. Start 2026-10-16 (actual); primary completion 2028-09-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
- Acronym
- MARITIME-T2D-3
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Maridebart cafraglutide
- Intervention (Drug)
- Semaglutide
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct07866066- Content hash
5405436d803879aef1a11267fbf14f397cc7b6de9b9db7c3bfb3ca572b738ca7